Skip to main content

Deutsche Bank Sticks to Their Sell Rating for AstraZeneca (AZN)

Tipranks - Tipranks - Sat Jan 17, 8:16AM CST

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Sell rating on AstraZeneca, with a price target of £110.00.

Claim 70% Off TipRanks Premium

Papadakis covers the Healthcare sector, focusing on stocks such as GlaxoSmithKline, Novo Nordisk, and AstraZeneca. According to TipRanks, Papadakis has an average return of 4.4% and a 54.04% success rate on recommended stocks.

Currently, the analyst consensus on AstraZeneca is a Moderate Buy with an average price target of p14,612.19.

See Insiders’ Hot Stocks on TipRanks >>

Based on AstraZeneca’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of p15.19 billion and a net profit of p2.53 billion. In comparison, last year the company earned a revenue of p13.96 billion and had a net profit of p1.47 billion

Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AZN in relation to earlier this year.

Read More on GB:AZN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).